GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (HAM:CSJ) » Definitions » Common Stock

CSL (HAM:CSJ) Common Stock : €492 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CSL Common Stock?

CSL's quarterly common stock increased from Dec. 2022 (€469 Mil) to Jun. 2023 (€477 Mil) and increased from Jun. 2023 (€477 Mil) to Dec. 2023 (€492 Mil).

CSL's annual common stock increased from Jun. 2021 (€-3,739 Mil) to Jun. 2022 (€458 Mil) and increased from Jun. 2022 (€458 Mil) to Jun. 2023 (€477 Mil).


CSL Common Stock Historical Data

The historical data trend for CSL's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Common Stock Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,073.66 -4,050.17 -3,738.82 457.68 477.19

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.15 457.68 469.45 477.19 492.43

CSL Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


CSL (HAM:CSJ) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

CSL (HAM:CSJ) Headlines

No Headlines